RenovoRx Analyst Ratings
BenzingaFeb 2 08:02 ET
RenovoRx Analyst Ratings
BenzingaNov 15, 2023 11:28 ET
Roth MKM Adjusts Price Target on RenovoRx to $13 From $14, Maintains Buy Rating
MT NewswiresAug 18, 2023 11:03 ET
Analysts Offer Insights on Healthcare Companies: Creative Medical Technology Holdings (CELZ), Boston Scientific (BSX) and RenovoRx (RNXT)
TipRanksJul 17, 2023 05:02 ET
Maxim Group Keeps Their Buy Rating on RenovoRx (RNXT)
TipRanksMay 18, 2023 07:25 ET
Maxim Group Remains a Buy on RenovoRx (RNXT)
TipRanksJan 19, 2023 14:30 ET
Analysts' Top Healthcare Picks: Flora Growth (FLGC), RenovoRx (RNXT)
TipRanksAug 17, 2022 07:40 ET
No Data
No Data